Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 296

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Open access
Schoenfeld, Adam J., Bandlamudi, Chai, Lavery, Jessica A., Montecalvo, Joseph, Namakydoust, Azadeh, Rizvi, Hira, Egger, Jacklynn, Concepcion, Carla P., Paul, Sonal, Arcila, Maria E., Daneshbod, Yahya, Chang, Jason, Sauter, Jennifer L., Beras, Amanda, Ladanyi, Marc, Jacks, Tyler, Rudin, Charles M., Taylor, Barry S., Donoghue, Mark T.A., Heller, Glenn, Hellmann, Matthew D., Rekhtman, Natasha, Riely, Gregory J.·2020·Clinical Cancer Research

Abstract

Purpose: SMARCA4 mutations are among the most common recurrent alterations in non–small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and clinical impact has not been established. Experimental Design: To characterize SMARCA4 alterations in NSCLC, we analyzed the genomic, protein expression, and clinical outcome data of patients with SMARCA4 alterations treated at Memorial Sloan Kettering. Results: In 4,813 tumors from patients with NSCLC, we identified 8% (n = 407) of patients with SMARCA4-mutant lung cancer. We describe two categories of SMARCA4 mutations: class 1 mutations (truncating mutations, fusions, and homozygous deletion) and class 2 mutations (missense mutations). Protein expression loss was associated with class 1 mutation (81% vs. 0%, P < 0.001). Both classes of mutation co-occurred more frequently with KRAS, STK11, and KEAP1 mutations compared with SMARCA4 wild-type tumors (P < 0.001). In patients with metastatic NSCLC, SMARCA4 alterations were associated with shorter overall survival, with class 1 alterations associated with shortest survival times (P < 0.001). Conversely, we found that treatment with immune checkpoint inhibitors (ICI) was associated with improved outcomes in patients with SMARCA4-mutant tumors (P = 0.01), with class 1 mutations having the best response to ICIs (P = 0.027). Conclusions: SMARCA4 alterations can be divided into two clinically relevant genomic classes associated with differential protein expression as well as distinct prognostic and treatment implications. Both classes co-occur with KEAP1, STK11, and KRAS mutations, but individually represent independent predictors of poor prognosis. Despite association with poor outcomes, SMARCA4-mutant lung cancers may be more sensitive to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-1825

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 296

Metadata

Authors
Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H., Egger, J., Concepcion, C. P., Paul, S., Arcila, M. E., Daneshbod, Y., Chang, J., Sauter, J. L., Beras, A., Ladanyi, M., Jacks, T., Rudin, C. M., Taylor, B. S., Donoghue, M. T. A., Heller, G., Hellmann, M. D., Rekhtman, N., & Riely, G. J.
Venue
Clinical Cancer Research
Published
2020-11-01
Volume
26
Issue
21
Pages
5701-5708
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3044448118
Cited by
296
References
33
FWCI
16.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1825
The paper
Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H., Egger, J., Concepcion, C. P., Paul, S., Arcila, M. E., Daneshbod, Y., Chang, J., Sauter, J. L., Beras, A., Ladanyi, M., Jacks, T., Rudin, C. M., Taylor, B. S., Donoghue, M. T. A., . . . Riely, G. J. (2020). The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1825

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.